Ascent Bridge Enters Framework Cooperation with Huanuosen to Foray into Gene Therapy Sector

NewTimeSpace News: On May 28, 2026, Ascent Bridge disclosed the signing of a framework cooperation agreement with Huanuosen to establish a joint venture named NewCo in Singapore. Ascent Bridge will hold no more than 70.1% of the shares, while Huanuosen will take a 19.9% stake, with the remaining 10% reserved for employee shareholding. Ascent Bridge is required to complete the incorporation of NewCo within three months and ensure its initial paid-in capital is no less than 20 million Singapore dollars.

According to the announcement, the joint venture will be responsible for the registration, clinical validation and commercialization of Gendicine in Singapore, as well as the construction of gene diagnosis and treatment centers in Singapore and Sanya, Hainan. Huanuosen will grant the exclusive rights of Gendicine for use in Singapore, and will receive an upfront payment of 20 million RMB, regulatory milestone payments of 30 million RMB, plus sales-based milestone payments capped at 1 billion RMB.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.